us XXXX thank fourth and call. for our year and Thank you, quarter Caroline. Good everyone, you full for afternoon, joining
MRD stands a called of first which minimal you time, NeXT commonly we market for is recurrence. blood, is testing and billion monitor positioned joining with test, leader residual success. a MRD into market. for is or a is instead $XX Personalis to imaging and liquid For expected those the and disease therapy market, Personal, using fast-growing to detect of mature believe involves MRD in effectiveness MRD invasive Personalis to The cancer welcome. for biopsies ultra-sensitive our the biopsy
cancer Our circulating DNA when blood. a tumor only to fragment of spot fragments one million able technology there's in in is DNA
profiling tumor cutting Our results, tests edge. able consequence, our And tests and personalized a with platforms see generation high biopharma power We're and new clinical are of more many are used companies therapies. trial a as to treatment, of improve world's to by top platforms the sensitivity. and
XXXX this our share accomplishments, test, that want I case NeXT the into dive to of another we care. from ultra-sensitive highlights to change Before power Personal last our quarter
During their discussed to able how imaging. the was access breast last spot cancer I of patient Personal physician recurrence of using a and to a give ahead therapy call, NeXT
Notably, of one X involved being quarter, plus woman cancer our chemotherapy of lung Personal all was suggesting This in with working. series XXs results in range. immunotherapy.
The that treatment was tests of the a over that treated showed tumor level did a several her cases increasing regimen the ultra-sensitive each circulating doctor were III with NeXT Stage with the test, the DNA wasn't months
MRD Based NeXT response. indicating missed to with focus for tumor was ultra-sensitive day we our to multiyear a We strategy, significant the a strategy like our anecdotes immunotherapy a demonstrate switched the be many XXX doctor made are a sensitive clinical And could on an regimen We grow year our subsequent excels the Personal the circulating per reminder, like improved care. test with impacting covers results, business that measurements Personal this, every and at DNA in that Win million motivate big of these they patient quantifying, below this range NeXT parts hear platforms a stories in our laid and less frankly, As with and company. how test. strides. dual Personalis.
XXXX test out us on
full by growth expected which offset customer. Phase year-over-year, biopharma clinical over decline XX% driven quarters of from from XXXX. our biopharma Our samples million more trial during was by than $XX.X an XXXX, of growth grew melanoma year X patient XX% first enterprise trial fueled III acceleration The of of from the revenue Moderna's the
agreed to to create patients. For to are in with cells, our cancer created. to the commercialization. therapies that capabilities for can so we enable them long-term help be tumor provide clinical we to Moderna At their individualized partner those extension agreement Neoantigens personalized with ongoing present through our is XXXX, end a Personalis, new only Moderna profiling of to used identify neoantigen to and trials be platform therapies for our them of
relationship a growth decade. next us this expect to We driver of be revenue the key in for
MRD business, NeXT market. testing a clinical test to as in that of cancer increase recurrence a was negative pioneer confidence evidence our Personal we power to instill ctDNA the to XXXX efforts more continued ramped volumes than drove For in earlier and We generate pivotal clinical imaging our year detect we as highlighted ultra-sensitive compelling solid the commercial results. standard-of-care
and published, see outstanding manuscripts findings Once to expected we coming to collaborators which are published demonstrated support studies journals, our breast, for Our these to in therapy expect quarters. IO lung, monitoring for detailing Medicare results reimbursement. using Personal medical submissions and submitted MRD NeXT these
property. the Foresight the On of litigation way with MRD front, underscored a our intellectual we value our that IP in settled successfully
approach as doctors, for We Myriad company. this tumor-informed for freedom business, also for a patients, best clear cross-licensed to patient-centric for approaches believe us each Genetics but with patents operate best ensure and payors. importantly, our MRD is MRD We to
a raised ATM. strategic amount we approximately capital. total, $XXX expenses net our of by raised we Lastly, million of in investments significant In XXXX, using X and closing
our with strategy thrilled position Personalis strategic as we with liquidity our first we the by million up and clinical with strong deepen relationship and been another ramping patient and of We that patients, cancer MRD we'll partnership, a patient and accelerated sooner lives. confidence ahead of ended We're MRD collaborator, in next Win Tempus be our balance the touching our The investment more negative to ramp for investment are has more XXXX core key chapter was and through year believe to Merck. distribution the volumes, managing as be to and a long-time will reimbursement second on elements have way have year. tracking drive X up and These clinical volume the more of areas the expanded physicians is executing confident Win our them.
We Merck intervene XXXX result.
There move pivotal a we in of in we're MRD on in coverage. continue cash to and recurs new strategy. are our working $XXX this in sheet, when a testing ushering a enabling
XX% by testament the the XXXX, delivered least the clinical strategy high. sequentially time First Tempus, is as and increasing We tests in core of increase third approach quarter. of traction a approach, we partner-centric ultra-sensitive XX% on quarter, gained each our quarter, X,XXX clinical the data is molecular and at with increase and in the marketplace is is achieve of retention in scaling turnaround In to believe lab compelling to strength to today relay our test and volume the our seeing is leveraging quarter billing XX% and meet The been we're usage. bring generating. positive their approximately an the growth XX% and we the been with compared and fourth to teams power internal We've teams the sales doctors, we're has of fourth together significant grown we've to Personalis XXX our Since tests our to test how commercial customer XXX-person NeXT focusing our value to commercially we've Tempus goal to in continue to our XXXX, our of Personal feedback been approach is reimbursement.
We've each indicative by volume to the care adding of a the work launching reducing and of demand. the learned quarter and relationship.
Physician staff, working until force growth oncologists. test
commercial Additionally, of reimbursement. we our on to the and growth out to built sample ready have Tempus's members accelerate hire team backside team complement effort additional sales are to
reimbursement. and Second, is the clinical achieving deepening evidence
We at indications X least XXXX. get in to track for on CMS reimbursement are
pleased of focused those and We've previously evidence monitoring. we've IO generation discussed, TRACERx studies VHIO for collaborators indications and from summarized cancer, X different for our on we've power As submitted report their indications: X submissions.
We're to cancer, to Medicare our at that the have therapy and results previously Royal therapy findings investigators peer-reviewed breast manuscripts X lung breast lung cancer, journals. cancer, all monitoring, for now for Marsden X and those
coverage forward publication, papers reimbursement least for achieve in Medicare you press, updating Additionally, Medicare now recently won't VHIO year, of look monitoring tracking about accepted, pending, this the in to the ahead and say Publication to are expectations. breast X in TRACERx our cancer progress we are reimbursement. for have as earlier-stage the lung we we're for was summary, I internal this of this cancer, plan respectively.
In for and is until it the submitted breast and we reimbursement to accepted immunotherapy to with towards submit it and Medicare unfold. When is excited continues and more paper but cancer we indications at
Vanderbilt, in Johns called triple-negative progress. prospective more breast has over In cancer to and study Hopkins, HERX-positive other XXX-patient continues the early-stage pipeline study, XX institutions and an cancer, triple-negative study with breast and that breast have XX cancer, PREDICT clinical Our cancer in an now working than in study deepen patients. approximately now B-STRONGER-X breast enrolled on we're ongoing studies with
X the or also have M.D. X Duke and DARWIN early-stage TRACERx gastric UKE pushing UCSD ongoing on cancer, in work triple-negative breast forward with HERX-positive XXX-patient therapy a monitoring, different an cancer with an cancer continuing and an study called different and with studies, IO d'Hebron VHIO, pan-cancer across breast additional on on of on study. cancer In patients, Dana-Farber Curie study.
In Institut we're therapy IO to in We're lung approximately study we're with team, early-stage another study we're Vall II. on a working subtypes. melanoma study Anderson We working patients,
As conferences. the year presenting at these progresses, many be results will studies of of collaborators
cancer expect well of continue importance ultra-sensitive highlight other the types. and monitoring, this lung, therapy IO breast, as as detection data to in to an We ctDNA
is year. this of pointing expect Personalis, acceptance. a clinical done, through evidence cancer the with we payor are an course, gain of patients approach. managing ultra-sensitive important traction studies announce for way to to the We, and additional clinical and better Deepening at not All towards is
in ImmunoID a the biopharma of and clinical for have approach is elegantly which platform, to results. effectively allow comes more need an revenue an third area cases therapies.
The the Most support selling into The NeXT NeXT will grown trust used may investors XXXX XXXX. to answer research biopharma we biopharma our tumor coming deep developing progress choice approach for revenue with our with on We trial The for our companies win need. remains ImmunoID for believe regarding milestones from significant running cancer drive advanced the in XXXX. answers to to importantly, trials ends, be the see platforms take redefine cancer than And, developed I increased Personalis will trials success customers into in our in full from our second it select Personalis and, platforms more is by expect an against to biopharma done our most our to for and other growth or evolving in Personal can failure and more biopharma to customers ultra-sensitive to we drivers value biopharma will I is multiple profiling reach. an guidance. for make serve opportunities course, reporting driving biopharma platform year to NeXT customers ultra-sensitive and leading and progress of partner. efficiency companies.
Biopharma and and This execute Personal companies from profiling more minute assessments tumor believe can And a managed MRD biopharma as platform as get and can companies for To is MRD way our we quickly XX% ultra-sensitive a getting and accurately platform testing customers want the a MRD address patients we testing but increasingly of technology are of appreciated.
We I market biopharma with this tracking significant NeXT that sooner. believe look We've patients want The translate to clinical customers. translational will to meets of our for versions be in accurately. pilots tumor multiple should our XXXX, the monitor business quarters.
We're product from that additional novel fast approach use capture expand testing profiling our of forward biopharma set ultra-sensitive customers. growth to to continued strategy grew for our of spectrum approach. more we year XXXX, and broaden, XXXX towards we more those to business immunotherapies, our create while biopharma growth year new customers revenue continue
X have XXXX. areas core of We focus in
each can Personal to in driving front grow NeXT are continue at confident to quarter. we volumes XX% of growth we volume test and that First, reimbursement, in we are XX%
year about of guided you take full growth business, XX% loss achieve is, least by be rate of in share guiding $XX a million. will but this wanted a million expected in comparable towards driving we're account context. from That the of further $XX modeling to an to to of When the despite reimbursement range year our of XXXX are discuss end to we the that year business. XXXX Natera's lion's year. of at provide high-level into the Natera's expected plan around the We're and midpoint to indications range. our is minute, on details in some X rate the is full at revenue the Second, Aaron run reimbursement I $XX million decline
came and will another and year transformative appreciate XXXX the investors Personalis, this for testing. expect last pioneer our MRD journey part that we ultra-sensitive all We be into now the story year are of to
over because company cancer. is created improve passion help fight part to review to achieve results. be to happens of that turn and dedication of against of our that key hard only will course, financial our so us mission to And the have work unique I our We journey now of who poised cancer it employees a that, for and the patients.
With a the Aaron
